BBattelle is a global research and development group that uses science and technology to solve big problems for the public good. It operates as an independent, not-for-profit organization and works with government agencies, commercial partners, and other collaborators. It focuses on fields like advanced materials, biology, chemistry, data science, and engineering to turn new scientific ideas into real, usable solutions. Its products and services come from a process of research, testing, and development that results in mission-ready applications that clients can deploy. Unlike some rivals, Battelle combines government contracting with commercial partnerships under a nonprofit umbrella, emphasizing a wide range of projects and a strong commitment to STEM education and community support. The company’s goal is to advance science and technology to benefit society, help its clients achieve their objectives, and invest in education and communities for long-term impact.
Work here?Claim your company
Industries
Company Size
5,001-10,000
Company Stage
Grant
Total Funding
$416M
Headquarters
Columbus, OH
Founded
1923
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$416M
Above
Industry Average
Funded Over
1 Rounds
Organ Procurement Organizations submit three new performance measures for national endorsement. Measures aim to strengthen accountability, improve performance, and save more lives MCLEAN, Va., Nov. 9, 2026 /PRNewswire/ - The Association of Organ Procurement Organizations (AOPO) announced the submission of three additional performance measures to the Partnership for Quality Measurement (PQM) for national endorsement, advancing a multi-year effort to strengthen accountability, improve organ procurement organization (OPO) performance, and save more lives through organ donation and transplantation. "We cannot improve this lifesaving system if we do not measure it accurately." - Dr. Jean O'Connor, Econometrica Inc. The new measures expand OPO performance evaluation beyond the initial stages of donation, providing greater insight into clinical practices and actionable opportunities for continuous quality improvement. They include: * Donor Management Goals (DMG) Bundle Rate: Assesses the effectiveness of donor care and identifies opportunities to optimize organ function and increase the number of organs available for transplant. * Organs Recovered Per Donor (ORPD) Rate: Evaluates the average number of organs recovered for transplantation from each deceased donor, regardless of whether the organs are ultimately transplanted. * Organ Utilization Rate: Evaluates the percentage of organs recovered that are ultimately transplanted into recipients. It provides insight into organ nonuse and opportunities for OPOs, transplant centers and other stakeholders to maximize utilization while maintaining patient safety. The submission builds on recent progress in AOPO's OPO Performance Measurement Project, launched in partnership with 53 OPOs and Econometrica, Inc. In October, two measures submitted earlier this year - Referral Rate and Approach Rate - earned national endorsement through PQM's independent, consensus-based review process. "Each step in the organ donation process presents opportunities to improve performance and ultimately save more lives," said AOPO President Allison Erickson. "These additional measures move us closer to a more complete understanding of OPO performance and provide meaningful data to guide quality improvements across the donation and transplantation system." PQM is operated by Battelle, which is contracted by the Centers for Medicare & Medicaid Services (CMS) as its Consensus-Based Entity for health care quality measure endorsement and maintenance. The independent review process evaluates measures for scientific soundness, relevance, feasibility, and potential to improve quality and accountability. Book Care Services Expanding Performance Measurement Across the Donation Process The current CMS framework for evaluating and re-certifying OPOs relies on just two outcome measures - Donation Rate and Transplant Rate - that have not undergone independent peer review or endorsement. While clinical outcomes are essential, these measures have well-documented flaws and limitations and do not fully capture the complexity of OPO performance or identify opportunities for meaningful improvement throughout the donation process. "We cannot improve this lifesaving system if we do not measure it accurately. These three new measures enable OPOs to isolate specific clinical activities that contribute to organ availability." said Econometrica Health Practice Area Director Dr. Jean O'Connor. "The measures also help promote donor safety and innovations that contribute to organ use by transplant programs. Securing national endorsement will help elevate best practices nationwide." Advancing a Comprehensive Framework for Quality Improvement Development of the measures has included collaboration with OPO professionals, clinicians, researchers, quality experts, donor families, transplant recipients, and other stakeholders. The project incorporates data analysis, measure testing, stakeholder feedback, and established CMS measure development standards. AOPO's quality improvement framework emphasizes the importance of evaluating process and outcome measures together. Building on this approach, AOPO will continue working with OPOs, policymakers, and other stakeholders to support the evaluation, implementation, and appropriate use of these measures. With more than 100,000 people awaiting lifesaving organ transplants nationwide, the public deserves performance measures that reflect the complexity of organ donation, strengthen accountability, and drive meaningful improvements to save lives. About the Association of Organ Procurement Organizations (AOPO) AOPO leads the nation's organ donation community to save and improve lives through organ, eye, and tissue donation. Founded in 1984, AOPO advances organ donation and transplantation by driving continual improvement of the donation process, collaborating with stakeholders, and sharing successful practices with its 45 member OPOs. AOPO envisions a future where every opportunity for donation results in lives saved. Visit aopo.org to learn more. SOURCE Association of Organ Procurement Organizations
Battelle, CMC Pharmaceuticals advance medical countermeasure program for U.S. Department of War. October 14, 2026 at 14:48 PM EDT i This article is third-party content and does not represent the views of this site. Tamar Securities, LLC make no guarantees regarding its accuracy or completeness. Battelle and CMC Pharmaceuticals are advancing work with the United States Department of War to develop improved medical countermeasures intended to protect American warfighters from nerve agent threats. The five-year, $40 million Acetylcholinesterase (AChE) Reactivator Development and Approval Pipeline (ARDAP) Prototype Program was awarded through the Defense Threat Reduction Agency, Joint Science and Technology Office (DTRA-JSTO). The program is focused on advancing a promising AChE reactivator candidate through the drug development pathway toward submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration. "Battelle has a long history of working with the DOW to develop medical countermeasures that protect military personnel from chemical threats," said Drew Cawthon, Business Line Director. "As the ARDAP program progresses toward IND submission, we are proud to continue supporting this important mission and to continue to drive next-generation solutions to emerging threats with a strong partner like CMC Pharmaceuticals." Ohio-based CMC Pharmaceuticals is supporting chemistry, manufacturing, and controls (CMC) activities, including laboratory development, cGMP testing, formulation and process development, stability evaluation, and Contract Manufacturing Organization oversight required to support product development and regulatory submissions. "We are excited to team with Battelle and provide our chemistry, manufacturing, and controls expertise to such an important program," said Mike Radomsky, President of CMC Pharmaceuticals. "Providing drug development services to the U.S. Department of War to protect our troops against the threat of nerve agents is truly an honor. This program adds to our existing and growing portfolio of improved therapeutics and medical countermeasures for the U.S. government." ARDAP is intended to establish a development and approval pipeline for improved AChE reactivators as medical countermeasures for nerve agent exposure. Battelle, CMC Pharmaceuticals, and program partners have advanced key CMC, nonclinical, clinical, and regulatory planning activities to support IND submission and future clinical evaluation. The effort is designed to support the efficient development of a fieldable medical countermeasure that could enhance the current standard of care for warfighters exposed to chemical threats. About Battelle Every day, the people of Battelle apply science and technology to solving what matters most. At major technology centers and national laboratories around the world, Battelle conducts research and development, designs and manufactures products, and delivers critical services for government and commercial customers. Headquartered in Columbus, Ohio since its founding in 1929, Battelle serves the national security, health and life sciences, and energy and environmental industries. For more information, visit www.battelle.org. About CMC Pharmaceuticals: CMC Pharmaceuticals is a leading provider of drug product development services and manufacturing support to the pharmaceutical and biotechnology industries. Located in Solon, Ohio, CMC Pharma delivers specialized scientific expertise and services including pre-formulation, formulation development, analytical development, cGMP lab services, stability and compatibility studies, manufacturing process development, CMO oversight, and consulting services to clients globally. Decades of specialized scientific experience in the development and manufacture of a wide range of drug product types including sterile injectables, solid oral, long-acting, controlled release, and other complex dosage forms. CMC Pharma has successfully managed a wide variety of pharmaceutical development programs, including multi-year programs with the federal government. For more information, visit www.cmcpharm.com. Contacts. Battelle Contact For more information contact Katy Delaney at (614) 424-7208 or at [email protected] or Amanda Ensinger at (614) 424-4087 or at [email protected]. CMC Pharmaceuticals Contact For more information contact Mike Radomsky at (415) 370-1139 or at [email protected] or contact Jared Heimovitz at (440) 637-5865 or at [email protected]. Report this content If you believe this article contains misleading, harmful, or spam content, please let Tamar Securities, LLC know.
Open RAN's AI era puts interoperability and testing in focus. Image: RCR Wireless News During the RCR Wireless News' Intelligent RAN Forum 2026, Viavi marketing manager Owen O'Donnell and Battelle vice president of product development Mark Reudink examined the evolution of open and intelligent RAN. In sum - what to know Openness expands innovation - Open RAN is bringing more vendors and solutions into the ecosystem, while network intelligence enables new use cases. Integration accelerates - Battelle's Mark Reudink said integration timelines for active antenna units have fallen from months to weeks as vendor software and testing platforms mature. AI needs validation - Viavi's Owen O'Donnell said testing is critical as AI applications influence network decisions and operators benchmark competing solutions. Open RAN and network intelligence are increasingly developing together, expanding the number of vendors, applications and use cases across the RAN ecosystem. But as intelligent applications become more prominent, interoperability, integration, and testing remain important challenges. The issues were discussed during the RCR Wireless News' Intelligent RAN Forum 2026, where Viavi Solutions marketing manager Owen O'Donnell and Battelle vice president of product development Mark Reudink examined the evolution of open and intelligent RAN. For O'Donnell, openness and network intelligence can provide operators with complementary benefits, including greater vendor participation and progress toward more autonomous networks. "I think, in a way, openness and network intelligence is nearly a perfect storm for the operators because the openness is bringing in new players, it's increasing the playing field, it's reducing the cost, while network intelligence is allowing operators to head towards the goal of fully autonomous networks," O'Donnell said. He said potential benefits include reduced capex and opex, faster time to market, more streamlined network operations, and increased competitiveness through innovation. Reudink said the Open RAN ecosystem has also matured from an integration perspective. He said Battelle's first integration of its active antenna radio unit with a distributed unit took months, but that timeline has subsequently fallen to weeks. Reudink also pointed to applications enabled by the broader ecosystem, including network steering and location solutions for factory floors where GPS may not be available. O'Donnell said the RIC has moved from being a specification on paper toward practical testing in production labs, while a growing range of use cases includes network-slice assurance, massive MIMO, signaling-storm detection, SMO scale testing, drone-swarm detection, and application-collision testing. O'Donnell also cited a Viavi and NTT Docomo demonstration involving AI-driven beamforming control that could improve system throughput by up to 20% by reducing control overhead. Testing remains important as Open RAN deployments become more complex, O'Donnell said. "The challenges are interoperability, integration, compliance and standards, security, increased attack surface, and regular software updates," he said. "So they're all the primary challenges that come with Open RAN." He said trust in AI applications is another major issue, particularly when applications are influencing network decisions without a human in the loop. AI applications are only as good as the data used to train them, while operator network data can be proprietary and confidential. O'Donnell said synthetic data can provide an alternative. Viavi's AI RAN Scenario Generator can create RAN scenarios, run iterations to train AI models and then validate their performance against scenarios. Reudink also emphasized the importance of common data approaches across vendors. "The data that comes in is fundamental to be able to have accurate AI models, to be able to really implement changes in that network, be it anything from smarter beam management to network steering," he said. The speakers also discussed the evolution of the AI-RAN Alliance and the move toward greater collaboration between vendors, operators, and other industry participants. Reudink said standardized metrics and data are important as multiple vendors and systems become involved. The discussion also highlighted the role of multi-vendor testing environments. O'Donnell said operators can benchmark competing AI applications in their own labs using real or tailored network scenarios, including evaluating energy savings alongside quality-of-experience impacts.
Battelle chooses Ennoia Technologies to help advance characterization of RavenStar Open RAN radio unit. Columbus, OH (BUSINESS WIRE) - Battelle, one of the world's largest independent nonprofit research and development organizations, announced today that it has selected Ennoia Technologies, Inc., an AI-RAN observability company, to advance performance characterization of the RavenStar(TM) Open RAN radio unit (O-RU). Battelle is applying Ennoia's agentic AI observability software to deepen the massive MIMO and beamforming performance analysis behind the radio, automating the O-RAN Open Fronthaul packet-level analysis using AI that currently takes significant manual effort. RavenStar(TM) is an ultra-wideband, steerable massive MIMO radio unit with an integrated antenna, designed and manufactured in the United States, operating across bands from 600 MHz to 7 GHz and supporting multiple protocols simultaneously from a single array. In February 2025, RavenStar(TM) became the first product validated under O-RAN and 3GPP test specifications at the VIAVI VALOR(TM) lab, achieving 99% of theoretical uplink and downlink throughput. In June 2026, it was awarded a National Spectrum Consortium contract to advance spectrum sharing technology. Ennoia's AI-RAN observability software captures and analyzes O-RAN Open Fronthaul traffic at IQ-sample resolution, allowing engineers to verify O-RAN compliance, measure massive MIMO and beamforming performance, and isolate root cause directly from the fronthaul. Its agentic AI automates the packet-level inspection that manual methods measure in weeks, completing the same analysis in minutes and making it practical to characterize and validate a massive MIMO O-RAN radio without extensive manual analysis. The software is non-intrusive and vendor-neutral, and runs entirely offline, keeping fronthaul captures and radio design data inside the customer's own environment. "Bringing a radio like RavenStar to market takes more than strong hardware - it takes rigorous, reproducible evidence that the design performs the way we say it does," said Mark Reudink, VP for Product Development at Battelle. "Ennoia's AI-driven fronthaul analysis software is intended to give us deep visibility into radio performance and to validate our design targets." "Fronthaul analysis has always been manual, expert-driven work measured in weeks, and that is exactly where AI-RAN based observability changes the equation," said Sridhar Rajagopal, Ph.D., Co-founder & Chief Executive Officer of Ennoia Technologies. "We are proud to work with Battelle and put that to work on a radio as advanced as RavenStar." About Battelle Every day, the people of Battelle apply science and technology to solving what matters most. At major technology centers and national laboratories around the world, Battelle conducts research and development, designs and manufactures products, and delivers critical services for government and commercial customers. Headquartered in Columbus, Ohio since its founding in 1929, Battelle serves the national security, health and life sciences, and energy and environmental industries. For more information, visit www.battelle.org. About Ennoia Technologies Ennoia Technologies, Inc. is an AI-RAN observability company building AI agents that deliver high-resolution visibility and analysis for the radio access network. Founded in 2025 and headquartered in Plano, Texas, Ennoia develops AI agents for wireless edge networks powered by small language models (SLMs), with a focus on intelligent planning, installation, and monitoring of RAN deployments. Its agent-based architecture is designed to reduce both CAPEX and OPEX by delivering deep, actionable insights down to the physical layer, using non-intrusive, vendor-neutral tools that run entirely offline to ensure privacy, portability, and resilience in the field. A member of the AI-RAN Alliance and a recipient of its 2025 Innovation Award, Ennoia helps operators, vendors, and researchers automate, validate, and optimize their 5G-Advanced and 6G networks with high resolution RAN visibility. For more information, visit www.ennoia-tech.com. (C) 2026 Business Wire, Inc. Like what you are reading? Join your peers
Battelle wins two 2026 Stevie Awards for Technology Excellence. Business Wire COLUMBUS, Ohio, August 18, 2026-(BUSINESS WIRE)-Battelle announced today that it has been named a winner in two categories in the third annual Stevie Awards for Technology Excellence. Battelle received gold and bronze honors for technologies that address STEM education and workforce development and next-generation wireless communications infrastructure. "This recognition reflects what's possible when education, industry and communities work together to prepare students for the future. At Battelle Education, we're focused on helping educators inspire students through meaningful STEM learning experiences while building pathways to high-demand careers," said Wes Hall, Senior Vice President Philanthropy and Education at Battelle. "We're honored that the Stevie Awards recognized both the promising impact of our programs today and their potential to strengthen tomorrow's workforce." Both of Battelle's nominations were selected from over 700 nominations submitted this year by organizations of all sizes in 37 nations and territories for consideration. More than 180 professionals worldwide participated in the judging process to select this year's honorees. "This recognition validates Battelle's vision for fundamentally rethinking wireless infrastructure. Judges noted RavenStar's innovation in multi-band, software-defined RF architecture and its potential to reduce infrastructure complexity while supporting future wireless standards," said Thomas Kent, business line director of Advanced Microsystem Solutions at Battelle. "We're proud to see that engineering innovation recognized as we continue advancing the technology toward broader deployment." Battelle's winning nominations for 2026 include: * Gold - The Battelle Education team was recognized as the "Educational or Research Institution of the Year" for the Education Technology category for transforming STEM learning at scale through innovative educator development and workforce readiness programs. Its initiatives, including the K-2 Nuclear STEM Education program, Battelle Teacher Academy and Manufacturing Pathways Pilot, have reached more than 2.3 million students, 5,000 educators and 3,000 schools and organizations, helping strengthen educator confidence, expand career-connected learning and prepare students for high-demand STEM careers. Judges praised the organization's measurable outcomes, scalable programming and significant workforce development impact.
Find jobs on Simplify and start your career today
We update Battelle's jobs every few hours, so check again soon!Browse all jobs
Industries
Company Size
5,001-10,000
Company Stage
Grant
Total Funding
$416M
Headquarters
Columbus, OH
Founded
1923
Find jobs on Simplify and start your career today
We update Battelle's jobs every few hours, so check again soon!Browse all jobs